The Columbia-Suicide Severity Rating Scale (C-SSRS) is the gold standard for assessing suicidal ideation, behavior, and risk. However, it is unclear whether the Patient Health Questionnaire-9 (PHQ-9) item 9 alone is sufficient for detecting suicidal ideation among patients with breast cancer. This study aimed to assess the validity of PHQ-9 item 9 compared to C-SSRS in female breast cancer patients undergoing psychiatric treatment.

In this study, we evaluated the validity of PHQ-9 item 9 compared to C-SSRS for identifying suicidal ideation among 176 female patients with breast cancer receiving psychiatric treatment, using self-reported questionnaires and leveraging demographic, clinical data, and statistical analyses to refine suicide risk assessment methods.

Among 176 patients, 35.2% showed a positive response to PHQ-9 item 9, 41.0% and 17.0% of them showed a response indicating wish for death and active suicidal ideation based on C-SSRS, respectively. The areas under the ROC curves for wish for death and active suicidal ideation were 0.840 and 0.842, respectively, indicating good discriminatory power with an optimal cut-off of 1/3 for both criteria.

Although PHQ-9 item 9 may have limited utility in detecting active suicidal ideation among patients with breast cancer, it may serve as a valuable screening tool for identifying those at risk of having thoughts of suicide accompanied by wish for death.

This study aimed to evaluate the postoperative recovery of urinary continence, complications, metabolic changes and urodynamic parameters in patients with bladder cancer undergoing radical cystectomy combined with orthotopic ileocaecal neobladder reconstruction and to explore the safety and functional feasibility of this surgical approach.

A retrospective analysis was performed on 45 bladder cancer patients who underwent radical cystectomy with orthotopic ileocaecal neobladder reconstruction at our hospital between January 2020 and January 2025. All patients received standardised postoperative follow-up, including urodynamic evaluations at 6 and 12 months, and rehabilitation training such as pelvic floor exercises, abdominal pressure-assisted voiding, and bladder sensation training. Clinical outcomes were assessed by comparing urinary continence, complications, biochemical parameters, and urodynamic indices at different postoperative time points.

At 3 months postoperatively, urinary incontinence (daytime and nighttime) was higher than at 6 months, indicating gradual improvement over time (p < 0.05). Early complications, mainly urine leakage and infections, were relatively common within 3 months but decreased thereafter, with few patients experiencing enterocutaneous fistula, urinary fistula, or urinary stones (p > 0.05). Postoperative haemoglobin and serum chloride decreased significantly (p < 0.05), while other biochemical parameters remained largely unchanged, except for an increase in blood urea nitrogen. Urodynamic assessments showed that by 12 months, neobladder maximum capacity and urinary flow rate increased significantly (p < 0.05), storage-phase bladder pressure decreased below urethral closure pressure (p < 0.05), voiding-phase pressures were unchanged (p > 0.05), and post-void residual volume was reduced (p < 0.05).

Orthotopic ileocaecal neobladder reconstruction after radical cystectomy is a safe and feasible urinary diversion. With standardised rehabilitation and follow-up, patients achieve satisfactory continence and stable metabolic and bladder function. However, long-term outcomes require validation in larger studies.

To investigate the application value of an operating room nursing protocol based on the Enhanced Recovery after Surgery (ERAS) concept in patients with prostate cancer undergoing laparoscopic radical prostatectomy (LRP).

A retrospective collection was conducted on patients who were scheduled to undergo LRP and admitted to the urology department of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from January 2024 to June 2025. The general preoperative, surgical-related and clinical data of the two groups of patients were collected and compared.

A total of 147 patients with LRP were collected during the study. These patients were divided into the traditional nursing (n = 73) and ERAS (n = 74) groups in accordance with different nursing plans. No significant difference was found in the general data of the two groups before surgery (p > 0.05). In the ERAS group, the moments marking the first discharge and exhaust, along with the lengths of time of urinary catheter indwelling and overall hospital stays, were all markedly shorter than those in the group receiving traditional nursing care, with the disparities between the two groups being statistically significant (p < 0.001). Additionally, the patients in the ERAS group exhibited a notably higher average urinary flow rate than their counterparts in the traditional nursing group (p < 0.001). The first voiding time of the patients in the ERAS group was earlier than that of the patients in the traditional nursing group (p < 0.001). At 8, 12, 24 and 48 h after surgery, the Numerical Rating Scale scores of the patients in the ERAS group were lower than those of the patients in the traditional nursing group (p < 0.001). The results of repeated analysis of variance revealed a significant difference in the time-group main effect (p < 0.001). The Incontinence Quality of Life Questionnaire scores of the patients in the ERAS group were higher than those of the patients in the traditional nursing group at three days after surgery and discharge (p < 0.001).

The operating room nursing protocol based on the ERAS concept has clinical value in patients with prostate cancer undergoing LRP.

Radical prostatectomy is the key for localised prostate cancer, but postoperative urinary incontinence and chronic pain impair outcomes. Enhancing perioperative care improves prognosis. This single-centre retrospective study evaluated a symptom management theory-based nursing model for radical prostatectomy patients.

A total of 165 patients were divided into the control (routine care, n = 75) and observation (symptom management nursing, n = 90) groups. After propensity score matching (PSM), 67 patients per group were analysed. Outcomes (pain: Visual Analogue Scale (VAS); Urinary incontinence: International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UISF); Negative emotions: Self-Rating Anxiety Scale (SAS)/Self-Rating Depression Scale (SDS); Quality of life: Functional Assessment of Cancer Therapy-Prostate (FACT-P)) were assessed before treatment, end of 2-week treatment and 1 month post-treatment. Three-month postoperative complications were compared.

At end of treatment and 1-month post-treatment, the observation group had lower VAS, ICIQ-UISF, SAS and SDS scores (all p < 0.05), higher FACT-P scores (all dimensions, p < 0.05) and lower urinary incontinence incidence (p < 0.05). The 3-month complication rate was 7.46% (5/67) vs 19.40% (13/67) in the control (p < 0.05).

Symptom management-based nursing alleviates pain, reduces urinary incontinence, relieves negative emotions, improves the quality of life and lowers complications, with clinical value for postoperative rehabilitation.

In this retrospective study, 150 cases of prostate cancer were evaluated to explore the ability of combined magnetic resonance imaging (MRI) features and nonspecific serum markers to distinguish clinically significant prostate cancer (csPCa) from nonclinically significant prostate cancer (ncsPCa) in patients with confirmed prostate cancer and to evaluate their application value in risk stratification.

This retrospective study analysed 150 patients with prostate cancer treated at our institution between May 2022 and May 2025. The patients were divided into csPCa (Gleason score ≥7) and ncsPCa groups (Gleason score = 6) according to Gleason score of pathology. Baseline clinical data and routine haematological and coagulation markers, including neutrophil count (NEU), lymphocyte count (LYM), fibrinogen (FIB), D-dimer and prostate-specific antigen (PSA) were collected. All patients subsequently underwent prostate-specific MRI following enrolment.

Significant difference in Prostate Imaging Reporting and Data System (PI-RADS) V2.1 score distribution was observed between the two groups (p < 0.05). The csPCa group also had higher neutrophil-to-lymphocyte ratio (NLR), FIB, D-dimer and PSA levels than the ncsPCa group (p < 0.05). Multivariate analysis confirmed these indicators as independent predictors of csPCa (p < 0.05). Receiver operating characteristic curve analysis showed the following area under the curve (AUC) values in diagnosing csPCa: 0.677 (95% confidence interval (CI): 0.571-0.784) for PI-RADS V2.1 score, with an optimal cutoff of 3.00; 0.738 (95% CI: 0.638-0.838) for NLR, with an optimal cutoff of 3.67; 0.769 (95% CI: 0.680-0.858) for FIB, with an optimal cutoff of 4.01; And 0.745 (95% CI: 0.639-0.852) for D-dimer, with an optimal cutoff of 0.595. The combined diagnostic model yielded an AUC of 0.839 (95% CI: 0.757-0.920) for identifying csPCa.

The combined use of prostate-specific MRI features and nonspecific serum markers (NLR, FIB and D-dimer) can effectively improve the diagnostic accuracy of csPCa.

Prostate cancer commonly affects older men. There is increasing interest in minimally invasive treatment options such as high-intensity focused ultrasound, which provides oncologic control with reduced side effects and functional preservation. We evaluated the oncologic and functional outcomes of whole-gland high-intensity focused ultrasound therapy for localized prostate cancer at a single tertiary center in Taiwan.

This retrospective study included 63 patients with primary localized prostate cancer with tumor stage ≤T2 and Grade Group 1-3 who were treated with whole-gland high-intensity focused ultrasound between July 2019 and October 2024. Outcomes included biochemical disease-free survival, prostate-specific antigen kinetics, and complication rates. Biochemical recurrence was defined using the American Society for Therapeutic Radiology and Oncology Phoenix criteria (nadir prostate-specific antigen level + 2 ng/mL). A contemporaneous group of patients that underwent robotic-assisted radical prostatectomy (RaRP) served as control.

The median preoperative prostate-specific antigen level was 8.58 ng/mL. Nadir prostate-specific antigen levels averaged 0.43 ng/mL and were reached after 2.90 months. At a median follow-up of 14.73 months, 20.63% of the patients had experienced disease progression. Higher initial prostate-specific antigen levels, prostate-specific antigen levels at the procedure, and older age were significantly associated with recurrence (p < 0.05). The overall complication rate was 30.16%, without a high Clavien-Dindo grade (4/5). Six patients (9.09%) required high-intensity focused ultrasound twice due to persistent or recurrent disease.

Whole-gland high-intensity focused ultrasound showed comparable short-term oncological outcomes with an acceptable rate of complications in selected patients with localized prostate cancer. Despite positive preliminary results, the lack of standardized surveillance protocols and the variability in outcome definitions require further prospective randomized studies.

The use of anticoagulant (AC) and antiaggregant (AG) medications is increasingly common in elderly patients undergoing urologic surgeries. This prospective observational study aimed to evaluate the influence of AC/AG therapy on bleeding-related complications following transurethral resection of the prostate (TURP), transurethral resection of bladder tumour (TURBT) and open prostatectomy (OP).

Patients who underwent TURP, TURBT or OP between March 2022 and January 2023 were included in this study. Patients were stratified according to AC/AG usage. Perioperative management details, including low-molecular-weight heparin (LMWH) bridging, were recorded. We evaluated parameters including duration of irrigation, length of stay, episodes of clot retention, transfusion rate and re-admission rate due to haematuria.

Among TURP patients, those using AC/AG therapy had significantly higher rates of transfusion (2.27% vs 0%, p = 0.038), postoperative clot retention (7.57% vs 0.53%, p = 0.008), re-catheterisation (9.09% vs 3.72%, p = 0.046) and re-admission due to haematuria (11.36% vs 3.72%, p = 0.008) compared with those not receiving AC/AG therapy. In the TURBT group, AC/AG use was associated with an elevated rate of rehospitalisation (p = 0.026). OP patients on AC/AG therapy experienced increased transfusion rates (p = 0.030), early postoperative clot retention (p = 0.034) and re-operations (p = 0.016). LMWH bridging was associated with further increases in irrigation volume, early clot retention and rehospitalisation, particularly in TURBT and OP patients.

AC/AG therapy significantly influences bleeding outcomes after TURP, TURBT and OP. LMWH bridging may further exacerbate these risks. This study emphasises the need for caution regarding bleeding-related complications in patients receiving AC/AG therapy.

The identification of reliable biomarkers for prostate cancer remains a pressing need in clinical oncology. Inflammatory and regulatory molecules such as NF-κB p65, apolipoprotein E (ApoE), angiopoietin-1 (Ang-1), forkhead box protein A2 (FOXA2), presenilin enhancer-2 (PEN-2) and β-amyloid precursor protein (β-APP) have been implicated in tumour biology. However, their roles in prostate cancer progression and invasion require further elucidation.

Serum levels of NF-κB p65, ApoE, Ang-1, FOXA2, PEN-2 and β-APP were measured in five distinct groups: Healthy controls, benign prostatic hyperplasia, non-treated prostate cancer, radical prostatectomy and metastatic prostate cancer. Quantification was performed using validated sandwich enzyme-linked immunosorbent assay (ELISA) kits (Elabscience®, Wuhan, China), with optical density readings at 450 nm. All measurements adhered strictly to manufacturer protocols. Receiver operating characteristic curve was analysed to calculate the area under the curve (AUC) for each biomarker.

ApoE (AUC = 0.83) and Ang-1 (AUC = 0.81) demonstrated the best diagnostic accuracy. PEN-2 (AUC = 0.81), FOXA2 (AUC = 0.79), and β-APP (AUC = 0.79) showed moderate-to-good discrimination, whereas NF-κB p65 (AUC = 0.76) exhibited moderate performance across disease stages.

Ang-1 and ApoE exhibited promising predictive potential in prostate cancer progression, whereas NF-κB p65 and PEN-2 demonstrated modest discriminative performance. FOXA2 showed expression variation across disease stages but lacked sufficient diagnostic value. These results highlight the diverse molecular profiles involved in prostate cancer biology and underline the need for validation in larger cohorts before clinical application.

This study aimed to compare the outcomes of open partial nephrectomy (OPN) and robot-assisted partial nephrectomy (RAPN) based on preoperative risk assessment using Martini's nomogram and postoperative trifecta and pentafecta criteria.

We retrospectively reviewed patients who underwent OPN or RAPN between 2017 and 2021. Renal function was assessed pre- and postoperatively using estimated glomerular filtration rate (eGFR) calculated by the Cockcroft-Gault formula. Baseline renal function was defined in accordance with the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. The Martini's nomogram was used preoperatively to estimate the risk of >25% postoperative eGFR decline; Surgical outcomes were evaluated in accordance with trifecta and pentafecta criteria.

A total of 103 patients were included (OPN: 63; RAPN: 40). The median follow-up was 77 (65-87) months. Median warm ischemia time was significantly lower in the OPN group (20 vs. 27.5 min, p < 0.001). Trifecta and pentafecta achievement rates were higher in the OPN group (65% vs. 25%, p < 0.001; 30.1% vs. 10%, p < 0.05, respectively). Martini's nomogram showed good discrimination in OPN (area under the curve (AUC) = 0.87) and RAPN (AUC = 0.80). Calibration analyses indicated overestimation in the OPN high-risk stratum, whereas the RAPN high/very-high strata were consistent with predictions.

In this retrospective cohort, OPN was associated with higher trifecta and pentafecta achievement than RAPN. The Martini's nomogram showed good discrimination but procedure-dependent calibration: Strata-level predictions aligned in RAPN, whereas risk was overestimated in the OPN high-risk stratum. These findings support cautious use for risk ranking and underscore the need for procedure-specific recalibration and further external validation, particularly for OPN.

Clinical cancer prevention and interception trials target high-risk populations and require agents with favorable risk-to-benefit ratios. Participant experiences are crucial in trial design, as highlighted in this issue of Cancer Prevention Research by Zahrieh and colleagues, which applied the "Was It Worth It?" questionnaire to evaluate participants' experiences in cancer chemoprevention trials. This study is the first examination of satisfaction in early-phase chemoprevention trials for high-risk individuals. This timely study underscores the need to assess and integrate participant and advocate feedback in completed, ongoing, and future trials. This spotlight commentary emphasizes the importance of participant experiences in enhancing trial designs for cancer prevention and interception. See related article by Zahrieh et al., p. 11.